Regen lab CEO Antoine Turzi discusses the evolution of regenerative medicine and the company's research focus in interview with SmartTRAK
Regenlab founder and CEO Antoine Turzi recently participated in an interview with SmartTrak to discuss the company’s journey in regenerative medicine, ongoing research initiatives, and perspectives on future developments in the field.
During the conversation, Turzi reflected on Regen lab’s more than 25 years of experience developing technologies designed to support the preparation of autologous biologic therapies. He highlighted the company’s long-standing focus on product standardization, quality systems, and clinical research across multiple therapeutic areas, including musculoskeletal health, wound care, aesthetics, and women’s health.
« From the beginning, our objective has been to develop technologies that support physicians through standardized preparation methods and a strong commitment to scientific evaluation, » said Turzi. « over the years, we have continued to invest in research, clinical studies, and quality systems that help advance the field of regenerative medicine. »
A key topic of the interview was Regen lab’s Cellular Matrix® technology, which combines platelet-rich plasma (PRP) and hyaluronic acid (HA) within a single preparation system. Turzi discussed the scientific rationale behind exploring combination approaches that integrate biologic components with biomaterial-based platforms, as well as the company’s efforts to evaluate these technologies through clinical research.
The discussion also addressed the importance of generating clinical evidence in highly regulated healthcare environments. Turzi emphasized the role of well-designed studies, regulatory compliance, and ongoing data generation in supporting the evaluation of emerging regenerative medicine technologies.
« Clinical research remains central to everything we do, » he noted. « The development of innovative technologies must be accompanied by rigorous evaluation, collaboration with healthcare professionals, and adherence to applicable regulatory requirements. »
Looking ahead, Turzi shared his perspective on future opportunities in regenerative medicine and tissue engineering. He highlighted growing interest in bioresorbable biomaterials and scaffold technologies that may support the next generation of regenerative approaches.
According to Turzi, continued innovation in this area will require the integration of biomaterials science, biologics, and clinical research to further expand understanding of how these technologies may be applied in patient care.
What makes Cellular Matrix different?
Discover the technology, scientific rationale, and clinical research behind Regen Lab’s PRP-HA platform.
Interested in seeing the technology in practice?
Connect with our team to discuss your needs, ask questions, and schedule a personalized product demonstration.